ZYNRELEF (bupivacaine/meloxicam) extended-release solution
Post-operative pain (soft tissue and orthopedic surgical procedures)
ApprovedCommercial
Key Facts
Indication
Post-operative pain (soft tissue and orthopedic surgical procedures)
Phase
Approved
Status
Commercial
Company
About Heron Therapeutics
Heron Therapeutics is a publicly traded biopharmaceutical company dedicated to developing non-opioid, long-acting therapeutics for acute care and oncology supportive care. The company has successfully transitioned to a commercial entity with two marketed products and a pipeline leveraging its proprietary Biochronomer® sustained-release delivery technology. Heron's strategic focus is on expanding the commercial footprint of its approved products while advancing its pipeline candidates to address complex pain and nausea/vomiting challenges, aiming to reduce reliance on systemic opioids and improve patient outcomes.
View full company profile